Farmas USA

LJPC

positive top-line results from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) in patients with catecholamine resistant hypotension (CRH).

The analysis of the primary efficacy endpoint, defined as the percentage of patients achieving a pre-specified target blood pressure response, was highly statistically significant: 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients (p0.00001). In addition, a trend toward longer survival was observed: 22% reduction in mortality risk through day 28 [hazard ratio=0.78 (0.57-1.07), p=0.12] for LJPC-501-treated patients.

tienen una fase 2 a liberar este semestre.

No me suena que la sigan por aqui, es muy pequeñita.

NOVN

ADXS

Advaxis (ADXS), SELLAS Enter Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy

Under the terms of the collaboration, Advaxis will conduct all pre-clinical activities required for an IND filing. Thereafter, SELLAS will be responsible for all clinical development and commercial activities. Advaxis will receive future payments of up to $358 million from SELLAS if certain development, regulatory, and commercial milestones are met. Following any regulatory approval of the product candidate emanating from this particular program, SELLAS has agreed to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization

http://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29%2C+SELLAS+Enter+Licensing+Agreement+for+Development+of+WT1+Antigen-Targeting+Immunotherapy/12595597.html?si_client=intbro

BCRX

Creo que alguno de por aquí la seguía. Saca noticia y empieza premarket en verde. Luego se tuerce. También ha sacado PR con resultados por encima de expectativas he leido en SA, por debajo en otro:

data below Street expectations, raises questions about competitiveness vs. injectable HAE drugs used in prevention.

Por lo que leo, no se entiende el movimiento. Puede ser buena entrada a largo. Si alguien la conoce, que se pronuncie.

The pre-specified per-protocol (PP) interim analysis included data on 24 subjects with confirmed Type 1 or Type 2 HAE completing 28 days of treatment (11 treated with BCX7353 and 13 with placebo). The mean rate of independently-adjudicated angioedema attacks for the pre-defined effective dosing period (weeks 2 through 4) in BCX7353-treated subjects was 0.34/week compared to 0.92/week for placebo, a reduction of 0.57/week (63%), p = 0.006. In the intent-to-treat (ITT) population of 28 subjects, the rates of attacks for the effective dosing period for BCX7353 and placebo groups were 0.44/week and 0.91/week, a reduction of 0.47/week (52%), p = 0.035.

A pre-planned analysis of peripheral and abdominal attacks showed reductions of 88% and 24%, respectively, for BCX7353 compared with placebo (PP analysis, weeks 2 through 4). To understand this difference, patient diaries were reviewed and abdominal attacks (n = 9, BCX7353 and n = 14, placebo) were subdivided into two groups: attacks with abdominal symptoms only and attacks with a combination of abdominal and peripheral symptoms (mixed attacks). This post-hoc analysis showed that there were 2, 2 and 7 peripheral, mixed and abdominal-only attacks on BCX7353 compared with 22, 12 and 2 attacks, respectively, for placebo. Based on this distribution, it is likely that subjects recorded transient abdominal adverse events as HAE attack symptoms in their diary.

https://globenewswire.com/news-release/2017/02/27/927908/0/en/BioCryst-Reports-Positive-Interim-Results-from-its-APeX-1-Trial.html

Y se deja más de un 6% en los primeros minutos de sesión... por favor, que alguien me lo explique.

HZNP

De perder los 16,15 ... los 15,2x se podrian poner a tiro esta semana ...

HZNP

HZNP

Dicen que las ventas anuales de RAVICTI bajan año tras año.